Absolute Abundance and Function of Intestinal Drug Transporters: A Prerequisite for Fully Mechanistic In Vitro-In Vivo Extrapolation of Oral Drug Absorption Publication Absolute Abundance and Function of Intestinal Drug Transporters: A Prerequisite for Fully Mechanistic In Vitro-In Vivo Extrapolation of Oral Drug Absorption The use of whole body physiological-based pharmacokinetic (PBPK) models linked with in vitro-in vivo extrapolation…CertaraJanuary 1, 2013
Simulations to Assess Phase 2 Non-inferiority Trials of Different Doses of Capecitabine in Combination with Docetaxel for Metastatic Breast Cancer Publication Simulations to Assess Phase 2 Non-inferiority Trials of Different Doses of Capecitabine in Combination with Docetaxel for Metastatic Breast Cancer A phase II trial in metastatic breast cancer (MBC) (NO16853) failed to show noninferiority (progression-free…CertaraDecember 26, 2012
Novel Biocompatible Disease Modifying Nanomedicine of VIP for Rheumatoid Arthritis Publication Novel Biocompatible Disease Modifying Nanomedicine of VIP for Rheumatoid Arthritis Despite advances in rheumatoid arthritis (RA) treatment, efficacious and safe disease-modifying therapy still represents an…CertaraDecember 4, 2012
Application of PBPK Modeling to Predict Monoclonal Antibody Disposition in Plasma and Tissues in Mouse Models of Human Colorectal Cancer Publication Application of PBPK Modeling to Predict Monoclonal Antibody Disposition in Plasma and Tissues in Mouse Models of Human Colorectal Cancer This investigation evaluated the utility of a physiologically based pharmacokinetic (PBPK) model, which incorporates model…CertaraDecember 1, 2012
What Can We Learn from a Human Mass Balance Study? Knowledge Base What Can We Learn from a Human Mass Balance Study? Mass balance studies are also called “C-14 studies” or “Absorption, Metabolism, and Excretion (AME) studies”.…CertaraNovember 27, 2012
Simulations Using a Drug-disease Modeling Framework and Phase 2 Data Predict Phase 3 Survival Outcome in First-line Non-small Cell Lung Cancer Publication Simulations Using a Drug-disease Modeling Framework and Phase 2 Data Predict Phase 3 Survival Outcome in First-line Non-small Cell Lung Cancer Simulations were performed for carboplatin/paclitaxel (C/P) plus motesanib or bevacizumab vs. C/P as first-line treatment…CertaraNovember 1, 2012
Characterization of Exposure Versus Response of Edoxaban in Patients Undergoing Total Hip Replacement Surgery Publication Characterization of Exposure Versus Response of Edoxaban in Patients Undergoing Total Hip Replacement Surgery Edoxaban is an oral direct factor Xa inhibitor approved for the prevention of venous thromboembolism…CertaraNovember 1, 2012
Trends in Oral Drug Bioavailability Following Bariatric Surgery: Examining the Variable Extent of Impact on Exposure of Different Drug Classes Publication Trends in Oral Drug Bioavailability Following Bariatric Surgery: Examining the Variable Extent of Impact on Exposure of Different Drug Classes Changes to oral drug bioavailability have been observed post bariatric surgery. However, the magnitude and…CertaraNovember 1, 2012
Designing a Clinical Drug-drug Interaction Study Knowledge Base Designing a Clinical Drug-drug Interaction Study After a much longer delay that I expected, I am back to blogging on a…CertaraOctober 29, 2012
A Pregnancy Physiologically-based Pharmacokinetic (p-PBPK) Model for Disposition of Drugs Metabolized by CYP1A2, CYP3A4, and CYP2D6 Publication A Pregnancy Physiologically-based Pharmacokinetic (p-PBPK) Model for Disposition of Drugs Metabolized by CYP1A2, CYP3A4, and CYP2D6 Pregnant women are usually not part of the traditional drug development program. Pregnancy is associated…CertaraOctober 9, 2012